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ABSTRACT 
IGF-I is a pivotal hormone in pediatric musculoskeletal development. Though recent data 
suggest that the role of IGF-I in total body lean mass and total body bone mass accrual may be 
compromised in children with insulin resistance, cortical bone geometric outcomes have not 
been studied in this context. Therefore, we explored the influence of insulin resistance on the 
relationship between IGF-I and cortical bone in children. A secondary aim was to examine the 
influence of insulin resistance on the lean mass-dependent relationship between IGF-I and 
cortical bone. Children were otherwise healthy, early adolescent black and white boys and girls 
(ages 9-13 years) and were classified as having high (n=147) or normal (n=168) insulin 
resistance based on the homeostasis model assessment of insulin resistance (HOMA-IR). 
Cortical bone at the tibia diaphysis (66% site) and total body fat-free soft tissue mass (FFST) 
were measured by pQCT and DXA, respectively. IGF-I, insulin and glucose were measured in 
fasting sera and HOMA-IR was calculated. Children with high HOMA-IR had greater 
unadjusted IGF-I (p<0.001). HOMA-IR was a negative predictor of cortical bone mineral 
content, cortical bone area (Ct.Ar) and polar strength strain index (pSSI; all p≤0.01) after 
adjusting for race, sex, age, maturation, fat mass, and FFST. IGF-I was a positive predictor of 
most musculoskeletal endpoints (all p<0.05) after adjusting for race, sex, age, and maturation. 
However, these relationships were moderated by HOMA-IR (pInteraction<0.05). FFST positively 
correlated with most cortical bone outcomes (all p<0.05). Path analyses demonstrated a positive 
relationship between IGF-I and Ct.Ar via FFST in the total cohort (βIndirect Effect=0.321, p<0.001). 
However, this relationship was moderated in the children with high (βIndirect Effect=0.200, p<0.001) 
versus normal (βIndirect Effect=0.408, p<0.001) HOMA-IR. These data implicate insulin resistance 
as a potential suppressor of IGF-I-dependent cortical bone development, though prospective 
studies are needed. This article is protected by copyright. All rights reserved 
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INTRODUCTION 
Nearly one third of US children have a body mass index (BMI) ≥ 85th percentile (for sex 
and age), and are thus considered overweight or obese.(1) Of the various adverse health 
characteristics that have been linked to childhood overweight and obesity, musculoskeletal health 
has received little attention, and data relating to the fat-bone relationship in children are mixed. 
For instance, greater tibia cortical bone strength has been shown in obese children versus their 
non-obese peers.(2) However, others have identified fat mass as a negative predictor of radius 
cortical bone strength during childhood,(3) lending an explanation for the greater propensity for 
skeletal fractures in overweight and obese youth.(4,5) Whereas transient fluctuations in insulin 
resistance accompany pubertal maturation,(6) obesity-related insulin resistance may underpin the 
fat-bone connection.(7,8) For instance, in the English boys and girls who participated in the Avon 
Longitudinal Study of Parents and Children, fasting insulin, an indicator of insulin resistance, 
was a negative predictor of mid-tibia cortical bone volumetric density, size, and estimated 
bending strength. Therefore, these data suggest that processes involved in cortical bone areal 
expansion may be affected.(8) 
Of the various hormones involved in pediatric skeletal development, insulin-like growth 
factor I (IGF-I) plays a pivotal role.(9-11) Indeed, IGF-I promotes bone mineral accrual and 
cortical bone areal expansion by acting directly upon the bone-forming osteoblasts; preferentially 
those located toward the periosteum.(12-14) In addition, the trophic effect of IGF-I on lean body 
mass is suspected to precede skeletal changes.(11,15-17) Therefore, IGF-I promotes cortical bone 
growth through both direct and lean mass-dependent processes. Moreover, IGF-I is similar to the 
pancreatic β-cell-derived insulin in terms of structure, downstream signaling processes, and 
cellular target tissues (e.g., muscle and bone).(18,19) Skeletal muscle is most prone to developing 
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insulin resistance and, as noted above, is an integral link between IGF-I and bone. Therefore, 
recent cross-sectional data showing a suppressed total body lean mass-dependent relationship 
between IGF-I and total body bone mass in girls with high insulin resistance may be attributed to 
suboptimal IGF-I action.(10) Cortical bone outcomes have yet to be studied in the context of 
insulin resistance, IGF-I, and pediatric bone; thus representing a key gap in the current body of 
evidence. In this study, we explored the influence of insulin resistance on the relationship 
between IGF-I and cortical bone in children. Considering the role of IGF-I in promoting cortical 
bone areal growth, we hypothesized that insulin resistance would moderate the relationship 
between IGF-I and cortical bone size, and consequently estimated bending strength. As a 
secondary aim, we examined the influence of insulin resistance on the lean mass-dependent 
relationship between IGF-I and cortical bone.  
METHODS 
Study participants  
This is a cross-sectional, ancillary study using baseline data from children who 
participated in the GAPI study (The University of Georgia [UGA], Purdue University [PU], and 
Indiana University [IU] multi-site, double blinded, randomized placebo-controlled vitamin D 
supplementation trial).(20,21) This secondary data analysis considers all participants with available 
data on the homeostasis model assessment of insulin resistance (HOMA-IR), and includes black 
and white males and females, ages 9 to 13 years, who were in the early stages of pubertal 
development (N=315). All children were recruited at sexual maturation rating stage 2 or 3 based 
on self-reported breast or genital development.(22-24) Potential participants were excluded from 
this study if they already commenced menarche (females), had a prior diagnosis of any chronic 
disease or growth disorder, or were using any medications and/or dietary/herbal supplements 
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known to influence musculoskeletal metabolism. “High” and “normal” HOMA-IR groups were 
determined using a HOMA-IR cutoff of 4.0.(25) Those designated as having normal HOMA-IR 
(i.e., HOMA-IR < 4.0) represent the group with “normal” insulin sensitivity, and those 
designated as having high HOMA-IR (i.e., HOMA-IR ≥ 4.0) represent the group with the 
greatest insulin resistance. The Institutional Review Board for Human Subjects at UGA, PU, and 
IU approved all study protocols and procedures. All participants and parents/guardians provided 
written informed assent and permission, respectively.  
Anthropometric measurements 
Weight was measured using an electronic scale, height was measured using a wall-
mounted stadiometer, and BMI percentiles (for sex and age) were calculated.(26) Single-measure 
intraclass correlation coefficients (ICCs) and test-retest coefficients of variation (CV) for height 
(0.99% and 0.4%) and weight (0.99% and 1.4%) were determined previously in our lab in 6 to 
10-year-old girls (N=10) who were measured by the same researcher twice over a 2-week 
period.(20) 
Dual energy X-ray absorptiometry 
Fat mass (kg), fat-free soft tissue mass (FFST; kg) and percent body fat (%) were 
measured via DXA at each study site (Delphi-A, Hologic Inc [UGA]; Lunar iDXA, GE Medical 
Instruments [PU]; and Discovery-W, Hologic Inc [IU]). The same researcher at each site 
performed and analyzed all DXA scans through instrument-specific software and procedures. At 
the UGA study site, ICCs were calculated from ten females ages 5-8 years who were scanned 
twice over a 7-day period (all ≥ 0.98). As reported previously,(20,21,27) DXA scanners at each 
testing site were cross-calibrated and regression formulae were derived and used to adjust data 
from UGA and IU to PU values.   
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Peripheral quantitative computed tomography 
As reported previously,(21) peripheral quantitative computed tomography (pQCT) scans 
were performed using Stratec XCT 2000 scanners (Stratec Medizintechnik GmbH, Pforzheim, 
Germany). To ensure comparability of machines between each testing site, a cortical bone 
phantom with known properties was scanned a minimum of 20 times on each scanner. The 
variation in phantom measures differed by < 1%. Scans were performed on the non-dominant 
lower leg, as determined by self-report. Tibia length (cm) was measured using the medial tibial 
plateau and the distal edge of the medial malleolus as points of reference. Relative to the total leg 
length and measured from the distal region, a pen mark was placed upon the 66% site of the tibia 
diaphysis. The lower leg was centered within the gantry while the subject was sitting upright and 
facing the instrument. The scan beam was placed upon the pen mark and a single tomographic 
slice was taken using a slice thickness of 2.3 mm, voxel size of 400 μm and a scan speed of 20 
mm/s.  
Using a threshold of 710 mg/cm3, cort mode 1 was used to determine cortical volumetric 
bone mineral density (Ct.vBMD, mg/cm3), cortical bone mineral content (Ct.BMC, mg/mm) and 
cortical bone area (Ct.Ar, cm2). Using this same threshold, contour mode 1 was used to define 
the outermost edge of the bone and peel mode 2, using a threshold of 400 mg/cm3, was used to 
separate the cancellous and cortical bone compartments. Total bone area (Tt.Ar, mm2), cortical 
thickness (Ct.Th, mm), periosteal circumference (Peri.Circ, mm) and endosteal circumference 
(Endo.Circ, mm) were measured. Cort mode 2 (threshold of 400 mg/cm3) was used to determine 
polar strength strain index (pSSI), which uses Ct.vBMD, section modulus, and normal 
physiological bone density that is estimated at 12,000 mg/mm3.(21,28,29) Muscle cross-sectional 
area (MCSA) was measured using a F03F05 filer (contour mode 3 [threshold of -100 mg/cm3] 
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and peel mode 2). At the UGA study site, test-retest reliability was performed by scanning five 
healthy females (ages 18 to 24 years).(30) One-way random effects model, single measure ICCs 
for all pQCT measurements were R ≥ 0.97. 
Serum biochemistries 
Blood samples were collected in the morning following an overnight fast and were stored 
in a -80 °C freezer until the time of analyses. Serum glucose was measured in triplicate using a 
microtiter modification of the enzymatic Autokit Glucose method (Wako Chemicals). The mean 
intra-assay CV for this analysis was 1.8% and the mean inter-assay CV was 2.2%. Serum insulin 
was assayed in duplicate using the Human Insulin Specific RIA (HI-14K, Millipore). The mean 
intra-assay CV for this analysis was 3.5% and the mean inter-assay CV was 5.3%. The 
homoeostasis model assessment of insulin resistance (HOMA-IR) was calculated (fasting insulin 
[uU/mL] x fasting glucose [mg/dL]/405).(31) As described previously,(10) serum IGF-1 (ng/mL) 
was measured in duplicate using a quantitative sandwich immunoassay technique with 
recombinant human IGF-1 (R&D Systems). Mean interassay CVs ranged from 5.6 to 8.7%. 
Statistical analyses 
Histograms of all variables were inspected for outliers and non-normal distributions. 
Non-normal distributions were corrected by performing log (insulin, HOMA-IR, IGF-I, FFST, 
fat mass, Tt.Ar, Ct.Th and pSSI) or square root (tibia length) transformations. The results of the 
descriptive comparisons using the transformed and untransformed values were similar. Thus, the 
untransformed data are presented in Table 1 for ease of interpretation. Unadjusted, between-
group differences in participant characteristics were determined using independent samples t-
tests and X-square tests.  
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The relationship between HOMA-IR and musculoskeletal endpoints was examined using 
liner regression while including race, sex, age, sexual maturation rating stage, and total body fat 
mass as covariates. Analyses involving cortical bone measures included FFST and tibia length as 
additional covariates. However, tibia length was not included as a covariate in the final analyses, 
as it did not alter the relationship between HOMA-IR and any cortical bone outcome.  
Linear regression analyses predicting musculoskeletal outcomes from IGF-I and FFST 
were performed. All analyses included race, sex, age, and sexual maturation rating stage as 
covariates. A two-step linear regression procedure was used to assess whether HOMA-IR 
moderated the relationship between IGF-I/FFST and musculoskeletal endpoints. In the first step 
of this procedure, the covariates, moderator variable (i.e., HOMA-IR), and independent variable 
were entered into the regression model. Second, the HOMA-IR by independent variable 
interaction was entered into the model, and the F change statistic was evaluated (i.e., pInteraction). 
This procedure was also performed while using group and sex as moderator variables. The 
above-mentioned statistical analyses were performed using SPSS version 23.  
The SPSS PROCESS program was used to perform a Model 58 moderated mediation to 
determine whether the indirect relation between IGF-I and Ct.Ar via FFST differed between 
HOMA-IR groups.(32) The index of moderated mediation, standard error, and the bias corrected 
95% confidence interval (10,000 bootstrap samples) were calculated. The index of moderated 
mediation was statistically significant (Supplemental Figure 1), indicating that 1) the IGF-I-
FFST-Ct.Ar relationship was moderated in those with high HOMA-IR and 2) that this difference 
was attributed to the suppressed path from IGF-I to FFST. Therefore, justifying the comparison 
of path analyses between the two groups. Using Mplus software (version 7.31), path analysis was 
performed to examine the FFST-mediated relationship between IGF-I and Ct.Ar. Indirect effects 
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tests were conducted using the product coefficient method.(33) Each of the above-mentioned path 
models were just-identified and included race, sex, and age as covariates. All significant p-values 
within each path analysis remained significant after adjusting for multiple comparisons through 
the Holm-Bonferroni technique. A p-value < 0.05 was considered statistically significant for all 
analyses.  
RESULTS 
 Descriptive participant characteristics are presented in Table 1. The high versus normal 
HOMA-IR group had a greater number of black and female participants, were on average more 
sexually mature, and had a greater body weight, BMI-for-age percentile, tibia length, FFST, fat 
mass, percent body fat, MCSA, insulin, glucose, HOMA-IR, and IGF-I (all p<0.05). With the 
exception of Ct.vBMD and Ct.Th, the unadjusted cortical bone outcomes were higher in the 
children with high HOMA-IR versus normal HOMA-IR (all p<0.01).  
After controlling for race, sex, age, sexual maturation rating stage, and fat mass, HOMA-
IR was a positive predictor of FFST and MCSA (both p<0.01; Table 2). However, HOMA-IR 
was a negative predictor of Ct.BMC, Ct.Ar, and pSSI after adjustment for race, sex, age, sexual 
maturation rating stage, fat mass, and FFST (all p≤0.01).  
IGF-I was a significant positive predictor of FFST, MCSA, Ct.BMC, Tt.Ar, Ct.Ar, Ct.Th, 
Peri.Circ, and pSSI in each of our analyses after adjusting for race, sex, age, and sexual 
maturation rating stage (Table 3). However, IGF-I was a negative predictor of Ct.vBMD and a 
positive predictor of Endo.Circ in our total cohort and normal HOMA-IR group only (all 
p<0.05). The relationship between IGF-I and FFST, MCSA, Ct.vBMD, Tt.Ar, Ct.Ar, Peri.Circ, 
Endo.Circ, and pSSI was moderated by HOMA-IR (all pInteraction<0.05). After additional 
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adjustment for FFST, IGF-I did not correlate with any of the cortical bone outcomes (data not 
shown).  
After adjusting for race, sex, age, and sexual maturation rating stage, FFST was a positive 
predictor of Ct.BMC, Tt.Ar, Ct.Ar, Ct.Th, Peri.Circ, Endo.Circ, and pSSI in each of our analyses 
(all p≤0.001, Table 4), but a negative predictor of Ct.vBMD in our total cohort and normal 
HOMA-IR group only (both p<0.005; pInteraction<0.005).  
The path models presented in Figure 1 represent the FFST-dependent relationship 
between IGF-I and Ct.Ar while controlling for race, sex, and age. In each of our analyses, IGF-I 
was a positive predictor of FFST and FFST was a positive predictor of Ct.Ar (all p<0.001). IGF-I 
did not predict Ct.Ar in any of the path models after controlling for the mediator, FFST. The test 
for an indirect effect was significant in the total cohort, high HOMA-IR group, and normal 
HOMA-IR group (all p<0.001). However, this relationship was moderated in the children with 
high HOMA-IR. The explained variability of Ct.Ar was 7% greater in those with normal versus 
high HOMA-IR.  
Relationships between HOMA-IR, IGF-I, and FFST with musculoskeletal outcomes 
while adjusting for covariates were tested in males versus females (Supplemental Table 1). 
HOMA-IR was positively associated with FFST (females and males) and MCSA (males), but 
negatively associated with Ct.BMC (females and males), Ct.Ar (males), and pSSI (males; all 
p<0.05). In both females and males, IGF-I was positively associated with FFST, MCSA, 
Ct.BMC, Tt.Ar, Ct.Ar, Ct.Th, Peri.Circ, and pSSI (all p<0.05). However, IGF-I correlated 
negatively with Ct.vBMD (p<0.05) and positively with Endo.Circ (p<0.005) in males only. The 
relationship between IGF-I and FFST, Ct.vBMD, Ct.BMC, and Ct.Ar was moderated in females 
(all pSex diff.<0.05). Whereas FFST was positively correlated with most cortical bone outcomes in 
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females and males (all p<0.05), FFST was negatively correlated with Ct.vBMD in males only 
(p<0.05; pSex diff.<0.05). 
DISCUSSION 
The primary aim of this study was to examine the influence of insulin resistance, as 
measured by HOMA-IR, on the relationship between IGF-I and cortical bone in children. These 
data show that the relationship between IGF-I and cortical bone are moderated in children with 
higher insulin resistance. In addition, insulin resistance suppressed the prediction of FFST and 
MCSA from IGF-I. Consequently, the lean body mass-dependent relationship between IGF-I and 
cortical bone was moderated in the children with higher insulin resistance. Considering the role 
of IGF-I in promoting cortical bone areal expansion, insulin resistance-related cortical bone size 
and strength deficits may be attributed to mechanisms involving IGF-I.  
To date, this is the first study to examine the IGF-I-cortical bone relationship within the 
context of insulin resistance. The role of IGF-I in musculoskeletal development during 
adolescence has been well characterized.(9,11,34) With respect to cortical bone, Xu and 
colleagues(11) showed in a cohort of Finnish girls that IGF-I was an important determinant of 
skeletal development, specifically in relation to periosteal expansion and cortical bone mass 
accrual, over a period of seven years. Likewise, in the current study IGF-I was a positive 
predictor of various cortical bone size and strength outcomes. However, we also identified 
inconsistencies in these relationships between the children with high versus normal HOMA-IR. 
Specifically, insulin resistance blunted the strength of the relationship between IGF-I and Tt.Ar, 
Peri.Circ, and Ct.Ar. In a liver-specific IGF-I-deficient mouse model (i.e., the LID mouse), 
Yakar et al(14) showed reductions in femoral cortical bone area and strength compared to wild-
type controls, yet tissue mineral density did not differ between the two. Indirectly, these data in 
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the murine model help clarify the negative relationship between IGF-I and Ct.vBMD. One 
explanation is that these inverse associations are attributed to the IGF-I-related preferential 
deposition of bone mineral toward the periosteum, therefore occurring at the expense of the 
inner-cortex. Taken together, the suppressed relationship between IGF-I and pSSI in the children 
with higher insulin resistance was attributed to IGF-I-related deviations in cortical bone size, 
rather than volumetric density (Figure 2). Moreover, it is plausible that the lower Ct.BMC, 
Ct.Ar, and pSSI in those with higher HOMA-IR involve IGF-I-related mechanisms. These 
results are of concern given that cortical bone bending strength is highly dependent upon areal 
dimensions(35) and that the majority of skeletal fractures sustained by children and 
adolescents,(36-38) particularly those with excess adiposity,(4,39) occur at long-bone sites of 
predominantly cortical bone.  
Accompanying the moderated IGF-I-cortical bone relationship, the children with high 
HOMA-IR also had lower FFST and MCSA relative to IGF-I. Lean body mass and MCSA are 
strong predictors of cortical bone areal measures(40-43) and are an integral link between IGF-I and 
bone.(10,11,42) Mouse(42) and human(10,11) studies have provided evidence supporting the facilitative 
role of lean body mass in the link between IGF-I and bone. In a previous cross-sectional study of 
premenarcheal girls,(10) our group showed an indirect relationship between IGF-I and total body 
bone mass via lean body mass. However, we also demonstrated that the IGF-I-lean body mass 
relationship was attenuated in the girls with higher insulin resistance (i.e., HOMA-IR > 4.0).(25) 
Likewise, in the current study, the relationship between IGF-I and Ct.Ar was FFST-dependent 
and was suppressed in the children with high versus normal HOMA-IR due to differences in the 
path from IGF-I to FFST. Between the two groups, we found an approximate 9% difference in 
explained variability of FFST in favor of those with normal HOMA-IR. If in fact IGF-I-
This article is protected by copyright. All rights reserved 39 
dependent lean mass and skeletal muscle accrual is hampered in children with insulin resistance, 
this may, in turn, have a downstream influence on skeletal development considering that muscle 
and lean mass growth precede and contribute to bone accretion.(40,44) We have speculated 
previously that the insulin resistance-related suppression of the IGF-I-FFST-total body bone 
mass relationship was accompanied by corresponding deficits in cortical bone geometry.(10) The 
results of the current study are in support of this hypothesis.  
Whereas the inevitable question, “Are children who are insulin resistant also IGF-I 
resistant?” remains unanswered, previous studies provide indirect evidence in support of this 
position. Insulin and IGF-I are similar in terms of structure, cellular target tissues (e.g., muscle 
and bone), and downstream signaling processes, specifically through the AKT/mTOR 
pathway.(18,19,45) As implied in the current study, lean body mass is a facilitator of the 
relationship between IGF-I and bone and is the primary site of insulin-mediated glucose 
uptake,(46) thus being most prone to fluctuations in insulin sensitivity. The bone-forming 
osteoblasts are also insulin-dependent and susceptible to impaired downstream signaling.(47) 
Factors that contribute to insulin resistance, such as chronic low-grade inflammation, 
compromise the myogenic and osteogenic effect of IGF-I.(48,49) Therefore, it is reasonable to 
suspect that the role of IGF-I in pediatric musculoskeletal development is altered in individuals 
with impaired glucose handling. Despite being tightly regulated throughout maturation, fasting 
serum glucose was higher in those with higher HOMA-IR. Hyperglycemia may lead to the non-
enzymatic glycation of bone collagenous proteins and consequently the accumulation of 
advanced glycation end products.(50) In addition to being directly implicated in skeletal 
fragility,(51-53) advanced glycation end products may modulate osteoblast IGF-I function.(54,55) 
Further, insulin promotes hepatic IGF-I production,(56) likely contributing to the ~20% greater 
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total IGF-I in the high HOMA-IR group. However, the majority of systemic IGF-I is bound to a 
variety of regulatory binding proteins. Due to alterations in IGF binding proteins, obese and/or 
hyperinsulinemic individuals may have a greater proportion of bioavailable relative to total IGF-I 
versus their healthier counterparts.(57) Therefore, we do not suspect that the insulin resistance-
related musculoskeletal inadequacies reported in the current study were attributed to differences 
in total and/or bioavailable IGF-I.  
When interpreting our findings, certain aspects of this study warrant consideration. First, 
making causal inferences based on our data would be inappropriate given the cross-sectional 
design. In addition, there are various unique attributes of pubertal maturation that are difficult to 
capture through cross-sectional analyses. For instance, cortical bone areal expansion and mineral 
acquisition lag behind longitudinal growth,(40,44) while fluctuations in insulin resistance occur 
normally during pubertal maturation.(6) Collecting prospective data throughout the adolescent 
years is an important next step in this line of inquiry. Moreover, consideration of sensitive 
measures of skeletal maturation will also enhance the understanding of whether or not excessive 
insulin resistance uncouples the coordinated process of musculoskeletal development. Second, 
we measured only total circulatory IGF-I concentrations and did not have data available on IGF 
binding proteins, so we can only speculate on differences in IGF-I bioavailability. Third, 
although HOMA-IR performs well against the oral glucose tolerance test in children,(58) 
including more dynamic measures of glucose metabolism would strengthen our methodological 
approach. Finally, whereas our sample size was sufficient to explore the intended research 
question, we were unable to perform analyses in groups stratified by race and sex. In accordance 
with one previous study,(8) relationships between insulin resistance and cortical bone did not 
differ between sexes. However, with respect to IGF-I, relationships with most musculoskeletal 
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outcomes were stronger in the males versus females while adjusting for covariates including 
race, age, and maturation. Data pertaining to the sex-dependency of the IGF-I-bone relationship 
in humans are scarce, yet animal studies indicate that the growth hormone/IGF-I axis, along with 
sex steroids, contributes to the cortical bone sexual dimorphism.(15) Given that insulin resistance 
is greater in females versus males during maturation,(6) it is plausible that the influence of insulin 
resistance on IGF-I-dependent musculoskeletal development differs by sex. Data from our 
previous study indicate that insulin resistance moderates the relationship between IGF-I and 
musculoskeletal outcomes in females who were at the early stages of sexual maturation.(10) 
However, additional work is needed to corroborate these findings in males. Furthermore, we 
were not adequately powered to include additional control variables into our path models. The 
influence of insulin resistance on the relationships between IGF-I and musculoskeletal endpoints 
was evident whether or not sexual maturation was included as a covariate. Therefore, we do not 
suspect this omission to be problematic. 
The unique strengths of this study include our utilization of path analysis statistical 
techniques for the testing of FFST as a mediator in the IGF-I-cortical bone relationship. 
Additionally, we included pQCT-derived measures of appendicular cortical bone geometry and 
strength, which addresses the most evident limitation of our previous work.(10)  
Conclusions 
This cross-sectional study corroborates the positive relationship between IGF-I and 
cortical bone size and strength outcomes in children, and we show for the first time that insulin 
resistance moderated these relationships. Given that lean body mass is an integral intermediary in 
the IGF-I-bone relationship and is prone to fluctuations in insulin resistance, our results may 
have been attributed to the suppressed lean body mass-dependent link between IGF-I and cortical 
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bone. Future studies examining the role of IGF-I in pediatric musculoskeletal development 
within the context of insulin resistance should include measures of IGF-I bioavailability and 
prospective data collected throughout the adolescent years, specifically in children with obesity-
related chronic health conditions. IGF-I is suspected to contribute to the sexual dimorphism 
observed in skeletal development.(15) Thus, whether insulin resistance influences the IGF-I-bone 
relationship differently in boys versus girls warrants exploration. Furthermore, biological factors 
associated with insulin resistance and hyperglycemia, for instance, biomarkers of inflammation 
and advanced glycation end products, also warrant consideration in subsequent studies. Since 
nearly one in four US children and adolescents is at risk of developing type-2 diabetes, a 
condition characterized by insulin resistance, it is a viable concern that IGF-I-dependent skeletal 
development is hampered in a relatively large subset of American youth.(59) 
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Figure Legends 
Figure 1. IGF-I predicts Ct.Ar via FFST in the total cohort, high HOMA-IR group, and normal 
HOMA-IR group. However, this FFST-dependent relationship is moderated in the children with 
high HOMA-IR. aRelationship between IGF-I and Ct.Ar through FFST. bRelationship between 
IGF-I and Ct.Ar while controlling for the mediator (i.e., FFST). Broken lines represent 
nonsignificant relationships.  
Figure 2. Schematic depicting the differences in the IGF-I-cortical bone relationship in the 
children with high versus normal HOMA-IR. The strength of the relationship between IGF-I and 
Tt.Ar, Ct.Ar, and Peri.Circ, was suppressed in the children with high HOMA-IR. However, IGF-
I was a negative predictor of Ct.vBMD (depicted by shading of the cortical compartment) and a 
positive predictor of Endo.Circ in the children with normal but not high HOMA-IR. 
Consequently, IGF-I was a stronger positive predictor of pSSI in those with normal versus high 
HOMA-IR (depicted by line thickness). *Significant IGF-I by HOMA-IR interaction 
(pInteraction<0.05) for the corresponding cortical bone outcome.  
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Tables 
 
 
 
 
Table 1. Participant characteristics 
  
Total Cohort High HOMA-IR Normal HOMA-IR 
pa 
N=315 n=147 n=168 
Demographics 
             Race (n; black)b  159  95 64 <0.001 
   Sex (n, female)b 154  86 68 0.001 
   Age (years) 11.3 ± 1.2 11.2 ± 1.3 11.5 ± 1.2 0.067 
   Sexual maturation stage 2.4 ± 0.5 2.4 ± 0.5 2.3 ± 0.5 0.022 
Anthropometrics 
   
 
 
  
 
     Height (cm) 150.7 ± 9.3 151.5 ± 9.3 150.1 ± 9.3 0.175 
   Weight (kg) 47.4 ± 12.1 52.1 ± 12.4 43.3 ± 10.3 <0.001 
   BMI-for-age (percentile) 68.2 ± 29.3 81.0 ± 21.5 57.0 ± 30.7 <0.001 
   Tibia length (cm) 35.0 ± 3.5 35.7 ± 3.2 34.3 ± 3.7 <0.001 
Body Composition 
   
 
 
  
 
     FFST (kg) 30.5 ± 6.9 31.7 ± 6.4 29.3 ± 7.1 0.002 
   Fat mass (kg) 14.7 ± 7.3 17.9 ± 8.0 11.9 ± 5.3 <0.001 
   Percent body fat (%) 31.0 ± 9.4 34.6 ± 9.5 27.9 ± 8.1 <0.001 
   MCSA (mm2) 4848.8 ± 1050.0 5071.4 ± 998.6 4655.7 ± 1058.1 <0.001 
Serum Biochemistries 
   
 
 
  
 
     Insulin (uU/mL) 19.9 ± 10.1 27.3 ± 10.2 13.4 ± 3.3 <0.001 
   Glucose (mg/dL) 89.0 ± 7.1 91.3 ± 7.2 87.0 ± 6.5 <0.001 
   HOMA-IR 4.4 ± 2.4 6.2 ± 2.4 2.9 ± 0.7 <0.001 
   IGF-I (ng/mL) 232.4 ± 97.9 256.3 ± 107.3 211.5 ± 83.7 <0.001 
Cortical Bone  
   
 
 
  
 
     Ct.vBMD (mg/cm3) 1062.6 ± 35.0 1066.7 ± 35.0 1059.1 ± 34.8 0.060 
   Ct.BMC (mg/mm) 252.2 ± 47.8 262.0 ± 48.0 243.7 ± 46.1 0.001 
   Tt.Ar (mm2) 446.6 ± 86.5 464.8 ± 87.2 430.8 ± 83.0 0.001 
   Ct.Ar (mm2) 237.4 ± 44.5 245.4 ± 43.1 230.4 ± 44.5 0.003 
   Ct.Th (mm) 3.8 ± 0.5 3.8 ± 0.5 3.7 ± 0.5 0.116 
   Peri.Circ (mm) 74.6 ± 7.2 76.1 ± 7.2 73.3 ± 6.9 0.001 
   Endo.Circ (mm) 50.9 ± 6.7 52.1 ± 6.9 49.8 ± 6.3 0.003 
   pSSI (mm3) 1684.2 ± 467.0 1786.7 ± 475.9 1594.9 ± 441.5 <0.001 
Data are presented as mean ± standard deviation unless otherwise indicated 
aTest of between-group significance based on independent samples t-test 
bTest of between-group significance based on X-square test 
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Table 2. Relationships between 
HOMA-IR and musculoskeletal 
outcomes while adjusting for covariates 
 
β p 
FFST 0.185 <0.001 
MCSA 0.149 0.007 
 
  Ct.vBMD -0.094 0.133 
Ct.BMC -0.128 <0.001 
Tt.Ar -0.065 0.111 
Ct.Ar  -0.116 0.001 
Ct.Th  -0.103 0.075 
Peri.Circ  -0.074 0.068 
Endo.Circ  -0.033 0.562 
pSSI  -0.090 0.010 
Each analysis includes, race, sex, age, 
sexual maturation rating stage and total 
body fat mass as covariates 
Analyses involving cortical bone 
outcomes also include FFST as an 
additional covariate 
 
  
Table 3. Relationships between IGF-I and musculoskeletal outcomes while adjusting for covariates 
 
Total Cohort 
 
High HOMA-IR 
 
Normal HOMA-IR 
pInteraction
a 
 
β p 
 
β p  β p 
FFST 0.431 <0.001 0.286 <0.001  0.510 <0.001 <0.001b 
MCSA 0.372 <0.001  0.238 0.012  0.424 <0.001 <0.001b 
 
         
Ct.vBMD -0.136 0.025  -0.048 0.581  -0.251 0.002 <0.001b 
Ct.BMC 0.301 <0.001  0.255 0.001  0.326 <0.001 0.097 
Tt.Ar 0.292 <0.001  0.211 0.020  0.337 <0.001 0.001 
Ct.Ar  0.332 <0.001  0.279 0.001  0.367 <0.001 0.019 
Ct.Th  0.277 <0.001  0.260 0.004  0.301 <0.001 0.435 
Peri.Circ  0.286 <0.001  0.212 0.019  0.327 <0.001 0.003 
Endo.Circ  0.176 0.005  0.110 0.274  0.206 0.012 0.012 
pSSI  0.322 <0.001  0.248 0.003  0.362 <0.001 0.002 
Race, sex, age, and sexual maturation rating stage were included as covariates for all analyses 
aRepresents the IGF-I x HOMA-IR interaction 
bIGF-I x group interaction p-value < 0.05 
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Table 4. Relationships between FFST and cortical bone outcomes while adjusting for covariates 
 
Total Cohort 
 
High HOMA-IR 
 
Normal HOMA-IR 
pInteraction
a 
 
β p 
 
β p  β p 
Ct.vBMD -0.195 0.002 -0.061 0.496  -0.280 0.002 0.001b 
Ct.BMC  0.690 <0.001  0.639 <0.001  0.771 <0.001 0.838 
Tt.Ar 0.747 <0.001  0.783 <0.001  0.747 <0.001 0.727 
Ct.Ar  0.736 <0.001  0.675 <0.001  0.811 <0.001 0.219 
Ct.Th 0.444 <0.001  0.300 0.001  0.569 <0.001 0.102 
Peri.Circ 0.748 <0.001  0.786 <0.001  0.750 <0.001 0.841 
Endo.Circ 0.586 <0.001  0.686 <0.001  0.521 <0.001 0.267b 
pSSI 0.750 <0.001  0.758 <0.001  0.785 <0.001 0.552 
Race, sex, age, and sexual maturation rating stage were included as covariates for all analyses 
aRepresents the IGF-I x HOMA-IR interaction 
bIGF-I x group interaction p-value < 0.05 
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